Hoth Therapeutics, Inc. (HOTH)
| Market Cap | 12.82M +13.3% |
| Revenue (ttm) | n/a |
| Net Income | -12.47M |
| EPS | -0.90 |
| Shares Out | 19.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 250,425 |
| Open | 0.6900 |
| Previous Close | 0.6940 |
| Day's Range | 0.6551 - 0.6925 |
| 52-Week Range | 0.4894 - 2.1150 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+646.16%) |
| Earnings Date | May 13, 2026 |
About HOTH
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for HOTH stock is "Strong Buy" and the 12-month stock price target is $5.0.
News
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment Disruptions NEW YORK, May 5, 2026 ...
Hoth Therapeutics reports results from HT-VA study
Hoth Therapeutics (HOTH) announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement, or CRADA, with the U.S. Department of Veterans Affairs and Em...
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity NEW YORK, April 14, 2026 /PRNewswire/...
Hoth Therapeutics reports positive HT-VA CRADA data
Hoth Therapeutics (HOTH) “announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement with the U.S. Department of Veterans Affairs and Emory Univer...
Hoth Therapeutics up 52% at $0.78 per share after HT-VA data
17:29 EDT Hoth Therapeutics (HOTH) up 52% at $0.78 per share after HT-VA data
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
NEW YORK, April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today ann...
Hoth Therapeutics announces $2M registered direct offering
Hoth Therapeutics (HOTH) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2.86M shares of its common stock at an offering
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today ann...
Hoth Therapeutics reports results from ongoing HT-001 program
Hoth Therapeutics (HOTH) announced positive clinical results from its ongoing HT-001 program, including achievement of the primary efficacy endpoint in interim analysis, with patients reaching an ARIG...
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDA...
Hoth Therapeutics announces issuance of Chinese patent
Hoth Therapeutics (HOTH) announced that the China National Intellectual Property Administration has granted Chinese Patent, titled “Targeting Kit with Splice Switching Oligonucleotides to Induce Apopt...
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
Technology Selectively Shuts Down Cancer Reproducing Cells Patent Covers Splice-Switching Oligonucleotide Platform Designed to Induce Apoptosis of Mast Cells NEW YORK, March 31, 2026 /PRNewswire/ -- H...
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
NEW YORK, March 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced the deployment of OpenClaw™, an advanced AI-enabled computa...
Hoth Therapeutics’ HT-001 shows positive PK, safety and clinical activity
Hoth Therapeutics (HOTH) reported “positive” pharmacokinetic – or PK -, safety, and clinical activity data for HT-001, demonstrating a ~77% increase in systemic drug exposure following repeat dosing, ...
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations . Safety and tolerability findings included: No serious a...
Hoth Therapeutics’ HT-VA shows cholesterol level restoration
Hoth Therapeutics (HOTH) announced new female-specific preclinical results from the second phase of its metabolic disease study evaluating glial cell-derived neurotrophic factor, or GDNF. The second p...
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female mice Treatment preserved hepatic autophagy and maintained norma...
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven Cancers NEW YORK, March 4, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceu...
Hoth Therapeutics announces expansion of CLEER-001 Phase 2a clinical trial
Hoth Therapeutics (HOTH) announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in Miami, Florida,
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment Option NEW YORK, Feb. 24, 2026 /PRNewswire/ -- Hoth Thera...
Hoth Therapeutics receives U.S. notice of allowance for Exon-skipping therapy
Hoth Therapeutics (HOTH) announced that the USPTO has issued a Notice of Allowance for “Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases.” The Notice of Allowance
Hoth Therapeutics’ HT-VA GDNF shows superior efficacy in obesity
Hoth Therapeutics (HOTH) announced “compelling” preclinical data from its VA-backed study on glial cell-derived neurotrophic factor, or GDNF, as a novel treatment for obesity and metabolic-associated ...
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model
In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Administration GDNF demonstrated superior efficacy compared with semaglutide (the active ingredient in Wego...
Hoth Therapeutics confirms it holds no cryptocurrency assets
Hoth Therapeutics (HOTH) announced over the last several days investors have contacted the company regarding Hoth’s exposure to digital assets such as Bitcoin, Solana and Ethereum. Hoth holds no crypt...
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with significant...